Digital Features for this AdisInsight Report can be found at https://doi.org/10.6084/m9.figshare.19172528

FormalPara Sotrovimab (Xevudy®): Key Points

A recombinant human monoclonal antibody is being developed by Vir Biotechnology and GlaxoSmithKline for the treatment of COVID-19

Received its first full approval on 17 December 2021 in the EU

Approved for the treatment of COVID-19 in adolescents (aged ≥ 12 years and weighing ≥ 40 kg) and adults who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19

1 Introduction

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of coronavirus disease 2019 (COVID-19), it has spread rapidly around the world, resulting in the currently ongoing COVID-19 pandemic [1]. Symptoms of COVID-19 can vary in severity, from being asymptomatic to being fatal, with older age and certain comorbidities, such as obesity, diabetes, chronic obstructive pulmonary disease and chronic kidney disease, being risk factors for severe COVID-19 [1]. The National Institutes of Health guideline recommends monoclonal antibodies for the treatment of non-hospitalized adults with mild to moderate COVID-19 who are at high risk of disease progression [2].

Sotrovimab (Xevudy®), a recombinant human monoclonal antibody targeted against the SARS-CoV-2, is being developed by Vir Biotechnology in collaboration with GlaxoSmithKline for the treatment of COVID-19. Sotrovimab neutralizes SARS-CoV-2 by binding to a highly conserved epitope located on the receptor binding domain (RBD) of the virus’ spike protein [3]. Preclinical studies indicate that the antibody provides a high barrier against viral escape and retains antiviral activity against newer SARS-CoV-2 variants that are associated with increased transmissibility and immune invasion, including Omicron variant (Sect. 2.1) [3, 4].

figure a

Key milestones in the development of sotrovimab for the treatment of COVID-19. *Evaluation of other monoclonal antibodies is ongoing; the estimated completion date of ACITV-3 is July 2022.

Sotrovimab received its first emergency use authorization in May 2021 in the USA for the treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 [5, 6], with similar interim, emergency or conditional authorizations subsequently granted in a number of other countries, including Bahrain, Brazil, Canada, Egypt, Japan, Kuwait, Saudi Arabia, Singapore, Qatar, Switzerland, Thailand and the United Arab Emirate [7,8,9,10]. On 17 December 2021, sotrovimab received its first full approval in the EU for the treatment of COVID-19 in adolescents aged ≥ 12 years and weighing ≥ 40 kg and adults who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19 [11, 12]. Sotrovimab was also granted provisional marketing authorization in Australia [13] and conditional marketing authorization in the UK [14].

The recommended dose of sotrovimab is 500 mg, administered as a single 30 min intravenous (IV) infusion; the solution must be diluted with 0.9% sodium chloride injection or 5% dextrose for injection prior to administration [11]. Sotrovimab is recommended to be administered within 5 days of COVID-19 symptom onset and should be administered in healthcare facilities where patients can be monitored during and at least 1 h after administration. The efficacy and safety of sotrovimab have not yet been established in children aged < 12 years or those weighing < 40 kg [11]. The recommended administration of sotrovimab (e.g. IV infusion duration and timing of administration) may differ between countries; please see local prescribing information for administration details.

In addition to IV administration, intramuscular (IM) administration of sotrovimab for the treatment of COVID-19 is being evaluated to increase patient access and convenience. In January 2022, an application for sotrovimab was submitted in the USA to expand its emergency use authorization to include IM administration [15].

1.1 Company Agreements and Patent Information

In February 2020, Vir Biotechnology and WuXi Biologics entered into a development and manufacturing collaboration for production of human monoclonal antibodies for the treatment of COVID-2019 [16]. Under the terms of the agreement, the companies will work together to develop, manufacture and commercialize Vir biotechnology’s proprietary antibodies. Once approved, Vir Biotechnology has the rights to commercialize products worldwide, except in Greater China where WuXi Biologics has the rights to commercialize products [16].

In March 2020, Vir Biotechnology entered into a license agreement with Xencor to gain a non-exclusive access to Xencor’s Xtend™ XmAb® Fc technology to extend the half-life of antibodies that are being investigated as potential COVID-19 treatments [17]. In March 2020, Vir Biotechnology also entered into a research collaboration with the National Institutes of Health Vaccine Research Center to characterize and develop antibodies against coronavirus, including SARS-CoV-2 [18].

In April 2020, Vir Biotechnology and GlaxoSmithKline signed a binding agreement to research and develop solutions for coronaviruses, including SARS-CoV-2 [19]. The collaboration will use Vir Biotechnology’s proprietary monoclonal antibody platform technology to identify and develop antibodies that could be used for the prevention and treatment of COVID-19 and other coronaviruses [19]. The collaboration agreement was expanded in February 2021 to include the research and development of new therapies for influenza and other respiratory viruses [20]. Under the terms of agreements, GlaxoSmithKline will make an equity investment in Vir Biotechnology [19]. In April 2020, Vir Biotechnology and Samsung Biologics entered into a manufacturing agreement under which the latter will manufacture SARS-CoV-2 antibodies VIR-7831 (sotrovimab) and VIR-7832 for the treatment of COVID-2019 [21].

In May 2020, Vir Biotechnology and Biogen entered a development and manufacturing agreement under which the latter will perform process development activities and provide specified manufacturing and process transfer services to enable commercial supply of Vir Biotechnology’s SARS-CoV-2 monoclonal antibody candidates, including sotrovimab [22]. The agreement complements its existing manufacturing agreements with WuXi Biologics and Samsung Biologics [22].

In January 2021, Eli Lilly entered an agreement with Vir Biotechnology and GlaxoSmithKline to evaluate the efficacy of bamlanivimab in combination with sotrovimab in the ongoing BLAZE-4 trial (completed in October 2021) in low risk patients with mild to moderate COVID-2019 [23, 24].

In Jul 2021, Vir Biotechnology and GlaxoSmithKline announced a joint procurement agreement with the European Commission to provide up to 220,000 doses of sotrovimab to participating member states [25]. As of January 2022, Vir Biotechnology and GlaxoSmithKline have announced purchase agreements of sotrovimab with numerous countries, including Australia [26], Canada [27], Singapore [28] and the USA [29, 30]. Through national agreements, the antibody is also supplied in Japan, Switzerland, UK and the United Arab Emirates [30].

As of December 2020, Vir technology has multiple US patent applications in the sotrovimab intellectual property portfolio with claims to the compositions of matters, pharmaceutical composition and methods of treatment, which are presently estimated to expire in 2041, absent any available patent term adjustments or extensions [31]. The patent portfolio also includes non-exclusively in-licensed patents and applications from Xencor, including 98 issued patents and 4 pending patent applications in various countries and jurisdictions for composition, methods of extending antibody serum half-life claims, pharmaceutical composition claims, method of treatment claims and process (methods of producing) claims, which are presently estimated to expire between 2021 and 2028, absent any available patent term adjustments or extensions [31].

2 Scientific Summary

2.1 Pharmacodynamics

Sotrovimab is a recombinant human monoclonal immunoglobulin G1 antibody that has been engineered with Xencor’s proprietary Xtend™ technology to enhance distribution in the lungs and to extend antibody half-life [4]. Sotrovimab binds with high affinity to a highly conserved epitope of the SARS-CoV-2 spike protein RBD (dissociation constant Kd = 0.21 nM), thereby suppressing viremia and accelerating infected cell clearance [32]. The antibody targets a RBD epitope that is outside the receptor binding motif and therefore does not compete with angiotensin converting enzyme 2 binding [3, 32].

In vitro, sotrovimab neutralized wild-type SARS-CoV-2 virus in a concentration-dependent manner, with a half maximal effective concentration (EC50) of 100.1 ng/mL [3, 32]. In a SARS-CoV-2 infected hamster model, sotrovimab significantly decreased weight loss (a surrogate for clinical disease), and total viral load and infectious virus levels in the lung [3, 32].

In vitro, sotrovimab displayed a high barrier to resistance to COVID-19 and neutralized pseudotyped viruses expressing spike monoclonal antibody resistance mutations that confer reduced susceptibility to bamlanivimab, casirivimab and/or imdevimab [3, 32]. Of note, reduced susceptibility to sotrovimab (as measured by changes in EC50 values) was observed with epitope variants K356T, P337H/L/R/T and E340A/K/G; however, the clinical impact of these variants is not yet known [3, 32].

On the basis of preclinical studies, the neutralization potency of sotrovimab is anticipated to be retained against a number of SARS-CoV-2 variants of interest, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Epsilon (B.1.427/B.1.429), Iota (B.1.526), Kappa (B.1.617.1), Delta (B.1.617.2), Lambda (C.37). Delta Plus (AY.1/AY.2), Mu (B.1.621) and Omicron (B.1.1.529) [3, 4, 11, 33, 34]. Notably, of all the tested monoclonal antibodies, including bamlanivimab, casirivimab, cilgavimab, imdevimab, sotrovimab and tixagevimab, only sotrovimab demonstrated significant neutralisation of Omicron variant in vitro [3, 33,34,35,36].

2.2 Pharmacokinetics

Following a single 1 h IV infusion of sotrovimab 500 mg, the mean maximum concentration (Cmax) was 117.6 µg/mL and the mean concentration on day 29 was 24.5 µg/mL; the median time to Cmax was 0.042 days [11, 32]. Based on non-compartmental analysis, the mean steady-state volume of distribution, the mean systemic clearance and the median terminal half-life was 8.1 L, 125 mL/day and ≈ 49 days, respectively [11]. Sotrovimab is degraded by proteolytic enzymes that are widely distributed in the body [11]. Of note, a phase I single-dose study (NCT04988152) to investigate the pharmacokinetics, safety and tolerability of IV or IM administration of sotrovimab versus placebo in Japanese and Caucasian participants was completed in December 2021.

Patient characteristics, including age and kidney or hepatic impairments, do not appear to have any clinically significant impact on the pharmacokinetics or elimination of sotrovimab [11]. Given that sotrovimab is not metabolized by CYP450 enzymes or renally excreted, drug-drug interactions between sotrovimab and drugs that are substrates, inducers or inhibitors of CYP450 enzymes or that are renally excreted are unlikely [11].

Features and properties of sotrovimab

Alternative names

GSK-4182136; VIR-7831; WBP 2275; Xevudy

Class

Antivirals; Monoclonal antibodies

Mechanism of action

Virus internalization inhibitor

Route of administration

Intravenous infusion; intramuscular

Pharmacodynamics

Binds to a highly conserved epitope located on the spike protein receptor binding domain of SARS-CoV-2

Pharmacokinetics

Reaches maximum plasma concentration within 0.042 days; volume of clearance 8.1 L, clearance 125 mL/day; terminal half-life ≈ 49 days; degraded by proteolytic enzymes

Adverse events

Diarrhoea, hypersensitivity reactions, infusion-related reactions

ATC codes

 

 WHO ATC code

J06B-D05 (Sotrovimab)

 EphMRA ATC code

J5 (Antivirals for Systemic Use)

2.3 Therapeutic Trials

Sotrovimab reduced the risk of disease progression in non-hospitalized adults with symptomatic, mild to moderate COVID-19 who are at high risk of progressing to severe disease in a multicenter, double-blind, placebo-controlled phase II/III COMET-ICE trial (NCT04545060) [37, 38]. Enrolled patients were aged ≥ 18 years, had tested positive for SARS-CoV-2 infection, confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) or antigen test, and had symptom onset within 5 days prior to randomization. Patients were also required to have ≥ 1 of the risk factors: aged ≥ 55 years, diabetes, obesity (body mass index > 30 kg/m2), chronic kidney disease (estimated glomerular filtration rate < 60 mL/min/1.73 m2), congestive heart failure (New York Heart Association class II–IV), chronic obstructive pulmonary disease or moderate to severe asthma. Patients with severe COVID-19 symptoms (shortness of breath at rest, < 94% oxygen saturation or requiring supplemental oxygen) were among those excluded [37, 38].

Patients were randomized to a single dose of sotrovimab 500 mg (n = 528) or placebo (n = 529), administered as a 1 h IV infusion [37, 38]. Randomization was stratified by age, duration of COVID-19 symptoms and region. Baseline demographic and disease characteristics were generally similar between the groups. In the intent-to-treat population, the most common pre-defined risk factors were obesity (63%), followed by aged ≥ 55 years (47%), diabetes (22%) and moderate to severe asthma (17%). Treatment was administered within 3 days or 4–5 days of COVID-19 symptom onset in 59% and 41% of patients, respectively [37, 38].

The proportion of patients who progressed to all-cause hospitalization for > 24 h or death due to any cause through day 29 (primary endpoint) was 1% in the sotrovimab group versus 6% in the placebo group, a significant (p < 0.001) relative risk reduction of 79% (95% CI 50–91%), with 0 and 14 patients in the respective groups requiring oxygen support or mechanical ventilation [38]. By day 29, there were no deaths in the sotrovimab group and 2 deaths in the placebo group [38].

Sotrovimab also provided significant (p ≤ 0.007) benefits over placebo for the first four key hierarchically tested secondary endpoints, which included all-cause emergency room visits, hospitalizations of any duration or deaths (adjusted relative risk reduction 66%; 95% CI 37–81%), change in viral load from baseline to day 8 (least square mean difference − 0.232 log10 copies/mL; 95% CI − 0.399 to − 0.065) in virology population (n = 733), progression to severe/critical respiratory COVID-19 requiring supplemental oxygen (adjusted relative risk reduction 74%; 95% CI 41–88%) and change in symptoms as measured by inFLUenza Patient-Reported Outcome (FLU-PRO) Plus total score from baseline to day 7 (least square mean difference − 1.07; 95% CI − 1.38 to − 0.76) [38]. All-cause mortality, one of the key hierarchical secondary endpoints, was not formally analysed due to a fewer number of anticipated deaths [38].

Primary endpoint was met in an ongoing, multicenter, randomized, open-label phase III COMET-TAIL trial (NCT04913675) indicating that IM administration of sotrovimab was noninferior to IV administration for the treatment of mild to moderate COVID-19 in non-hospitalized, high-risk adolescents aged ≥ 12 years and adults (n = 983) [10]. Following IM or IV administration of sotrovimab 500 mg, progression to all-cause hospitalization for > 24 h or death due to any cause through day 29 occurred in 2.7% and 1.3% of patients, respectively; the adjusted difference between the administrations was 1.07% and the upper bound of the 95% CI did not exceed the predetermined noninferiority margin of 3.5% (primary endpoint) [10].

In a prospective, propensity-matched observational cohort study in non-hospitalized patients with mild to moderate COVID-19 due to Delta variant (n = 3069), casirivimab plus imdevimab or sotrovimab treatment significantly reduced the risk of hospitalization or death by 28 days compared with no treatment (risk ratio 0.4; 95% CI 0.28–0.57), with the comparative effectiveness between the treatments appearing to be similar [39]. In addition, in an ongoing randomized, parallel-assignment, open-label phase III OPTIMISE-C19 trial (NCT04790786) in patients with COVID-19 who received casirivimab plus imdevimab (n = 2454) or sotrovimab (n = 1104), the median hospital-free days were 28 days [39].

Interim futility analyses of two neutralizing monoclonal antibody therapies, namely sotrovimab and BRII-196 plus BRII-198, in a multinational, double-blind, randomized placebo-controlled phase III ACTIV-3 trial (NCT04501978) in hospitalized adults with COVID-19 have been reported [40]. There was no significant (based on 95% CI) difference between sotrovimab (n = 182) and placebo (n = 178) recipients with respect to a more favourable category on the pulmonary scale at day 5 (adjusted odds ratio 1.07; 95% CI 0.74–1.56), a more favourable category on the pulmonary-plus complication scale at day 5 (1.08; 0.74–1.58) and a more favorable sustained clinical recovery by day 90 (adjusted rate ratio 1.12; 0.91–1.37). Enrolment in the sotrovimab arm was halted on the basis of the analysis [40].

Preliminary positive topline results from a randomized, double-blind, placebo-controlled phase II BLAZE-4 trial (NCT04634409) in low-risk adult patients with mild to moderate COVID-19 have been reported [41]. Combination therapy of bamlanivimab 700 mg with sotrovimab 500 mg significantly (p < 0.001) reduced the percentage of patients with high viral load (i.e. viral load > 5.27) by 70% at day 7 versus placebo (primary endpoint). In addition, there were no COVID-19 related hospitalization or death by day 29 and the combination therapy significantly reduced the mean SARS-CoV-2 viral load relative to placebo from baseline to days 3, 5 and 7 [41].

Key clinical trials of sotrovimab

Drug(s)

Indication

Phase

Status

Location(s)

Identifier

Sponsor (collaborator)

Sotrovimab

Treatment of COVID-19 (non-hospitalized)

IV

Recruiting

United Arab Emirates

NCT05144178, No108/2021EHS

Emirates Health Services

Sotrovimab, casirivimab/imdevimab, molnupiravir

Treatment of COVID-19 (observational cohort)

IV

Recruiting

Netherlands

NCT05195060, NL78705-018-21, TURN-COVID

Academisch Medisch Centrum—Universiteit van Amsterdam

Sotrovimab (IM) and (IV)

Treatment of COVID-19 (non-hospitalized)

III

Ongoing

Multinational

NCT04913675, EudraCT2021-000623-13, P024-2021, VIR7831-5008, COMET-TAIL

GlaxoSmithKline, Vir Biotechnology

Sotrovimab, amubarvimab, bamlanivimab, cilgavimab/tixagevimab, ensovibep, romlusevimab

Treatment of COVID-19 (hospitalized)

III

Completeda

Multinational

NCT04501978, EudraCT2020-003278-37, 014ACTIV3, INSIGHT014, ACTIV-3

AstraZeneca, Brii Biosciences, Eli Lilly, GlaxoSmithKline, Molecular Partners AG, Novartis, NRx Pharmaceuticals, Pfizer, Vir Biotechnology

Sotrovimab, bamlanivimab, bamlanivimab + etesevimab, casirivimab/imdevimab

Treatment of COVID-19 (non-hospitalized)

III

Ongoing

USA

NCT04790786; OPTIMISE-C19

University of Pittsburgh, Berry consultants

Sotrovimab (IV), placebo

Treatment of COVID-19 (non-hospitalized)

II/III

Completed

Multinational

NCT04545060, GSK-Study214367, VIR7831-5001, COMET-ICE

GlaxoSmithKline, Vir Biotechnology

Sotrovimab, aspirin, casirivimab/imdevimab, colchicine, corticosteroid, immunoglobulin, tocilizumab, anakinra; azithromycin; convalescent plasma, baricitinib, empagliflozin, hydroxychloroquine, lopinavir/ritonavir, infliximab

Treatment of COVID-19 (hospitalized)

II/III

Recruiting

Multinational

NCT04381936, EudraCT2020-001113-21, 50189673, RECOVERY

University of Oxford, UK research and innovation, National Institute for Health Research, Bill and Melinda Gates Foundation

Sotrovimab (IV), bamlanivimab (IV), bebtelovimab (IV), etesevimab (IV), placebo

Treatment of COVID-19 (non-hospitalized)

II

Completed

Multinational

NCT04634409, 18160, J2X-MC-PYAH, BLAZE-4

Abcellera, Eli Lilly, GlaxoSmithKline, Junshi Biosciences—Impact Therapeutics, Shanghai Junshi Biosciences, Vir Biotechnology

Sotrovimab (IV) and (IM)

Treatment of COVID-19 (non-hospitalized)

II

Ongoing

Multinational

NCT04779879, EudraCT2021-000724-35, 216912, VIR7831-5006, GSK-Study216912, COMET-PEAK

GlaxoSmithKline, Vir Biotechnology

Sotrovimab (IV) and (IM)

Treatment of COVID-19 (non-hospitalized children)

II

Recruiting

Multinational

NCT05124210, EudraCT2021-003717-18, 215226, 215226VIR7831-5005, P468/2021, COMET-PACE

GlaxoSmithKline, Vir Biotechnology

Sotrovimab (IV)

Prevention of COVID-19

II

Recruiting

USA

NCT05210101

GlaxoSmithKline

Sotrovimab (IV)

Prevention of COVID-19

I

Recruiting

USA

NCT05135650; COVIDMAB

Vir Biotechnology

  1. COVID-19 coronavirus disease 2019, IM intramuscular, IV intravenous
  2. aEvaluation of other monoclonal antibodies is ongoing

2.4 Adverse Events

In the COMET-ICE study in patients with mild to moderate COVID-19, the overall incidence of adverse events (AEs) in the sotrovimab (n = 523) and placebo (n = 526) groups was 22% and 23%, with the most common (> 1%) AE occurring more frequently with sotrovimab than placebo being diarrhoea (2% vs < 1%) [38]. Serious AEs and grade 3 or 4 AEs occurred in 2% and 3% of sotrovimab recipients versus 6% and 7% of placebo recipients, respectively; no serious AEs were considered to be related to sotrovimab. During the study (including follow-up period), there were no deaths in the sotrovimab group and four deaths in the placebo group (due to COVID-19 pneumonia, pneumonia or respiratory failure). The incidence of systemic infusion-related reactions (including hypersensitivity reactions), an AE of special interest, was low and similar between the treatment groups (1% in each group), with all reactions being grade 1 or 2 in severity. Results from the COMET-ICE study suggest that sotrovimab is not associated with antibody-dependent enhancement [38].

In the COMET-TAIL study, serious AEs and grade 3 or 4 AEs were rare in patients receiving IM or IV administration of sotrovimab [10].

2.5 Ongoing Clinical Trials

In addition to the ongoing phase III COMET-TAIL (NCT04913675; Sect. 2.3) and OPTIMISE-C19 (NCT04790786; Sect. 2.3) trials, a multinational, randomized, double-blind phase II trial (COMET-PEAK; NCT04779879) to evaluate the safety and pharmacokinetics of a second generation sotrovimab in non-hospitalized patients with mild to moderate COVID-19 is ongoing. Recruitment is underway in a multinational, randomized, open-label phase II/III trial (RECOVERY; NCT04381936) to evaluate the safety and efficacy of multiple treatments, including sotrovimab, in hospitalized patients with COVID-19. Also recruiting is an open-label phase II trial (COMET-PACE; NCT05124210) to evaluate the pharmacokinetics, pharmacodynamics and safety of sotrovimab in paediatric patients aged < 18 years with mild to moderate COVID-19 who are at high risk of disease progression.

A prospective observational study (TURN-COVID; NCT05195060) in Netherlands is recruiting patients to evaluate the use of neutralizing monoclonal antibodies, including sotrovimab, and other antiviral agents for the treatment of COVID-19. Recruitment is also underway in a retrospective observational study (NCT05144178) in the United Arab Emirates to evaluate the efficacy of sotrovimab in ambulatory patients with early symptomatic COVID-19 who are at high risk for hospitalization.

Sotrovimab is also being investigated for the prevention of COVID-19. An open-label phase II trial (NCT05210101) is recruiting immunocompromised patients with impaired humoral immunity against SARS-CoV-2 to examine the tolerability of IV sotrovimab when administered as prophylaxis for COVID-19. A phase I study (COVIDMAB; NCT05135650) is recruiting patients undergoing hematopoietic stem cell transplantation to evaluate the pharmacokinetics of sotrovimab when administered as pre-exposure prophylaxis for COVID-19.

3 Current Status

Sotrovimab received its first full approval on 17 December 2021 for the treatment of COVID-19 in the EU [11, 12].